Cardio-Renal panel to address Revatio, phosphate binders
Executive Summary
FDA's Cardiovascular and Renal Drugs Advisory Committee will meet Oct. 16 to discuss extending the use of phosphate binders to the pre-dialysis population. Shire, Genzyme and Fresenius - all of whom have phosphate binders approved for use in controlling serum phosphorus levels in dialysis patients - are scheduled to speak at the first day of the meeting. Genzyme has an NDA pending for Renagel (sevelamer) follow-on Renvela for the pre-dialysis indication. Fresenius markets PhosLo (calcium acetate) and Shire markets Fosrenol (lanthanum) in the United States. The panel will also discuss data requirements and study designs for a pediatric indication for Pfizer's Revatio (sildenafil) in pulmonary arterial hypertension Oct. 17...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.